Jenburkt Pharmaceuticals released its Q4 financial results, showing significant growth. Revenue increased by 5.80% to ₹410.50 crore. EBITDA rose by 10.25% to ₹108.60 crore, with the EBITDA margin expanding to 26.45%. Net profit grew by 8.10% to ₹85.40 crore. The company also announced a dividend of ₹18.00 per equity share.